RE:RP2DMaybe its time to quit making assumptions about timing and results.....Wild speculation at best....If you want answers maybe you should change your mind about meeting with management
SPCEO1 wrote: The RP2D, or recommended phase 2 dosage, is one step below the MTD. So, the 300mg dosage level, or about 1.5x the normal docetaxel dose seems to be the early leader for the RP2D. The higher the dosage level TH can use in phase 1b and phase 2, the better the chances of success. In the pre-clinical charts, the best results were gleaned when the dosage of TH-1902 was a little more than 2x that of docetaxel. So, ideally, the 420mg level would be the RP2D.
Does anyone have any idea why TH does not want to share more specific information on the number of patients dosed at 420mg, whether this is the second time at this level and exactly how long it now looks like it will take them to complete the trial. JFM was ironically suggesting the summer for the trial's end earlier but that could turn out to be correct.
I really do not understand why TH management has allowed us to be so confused about these basic matters. They already have a credibility problem and these delays are not helping fix that.